{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-002514","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.697205+00:00","generated_at":"2026-06-27T19:13:48.685649+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CVRx preliminary Q4 rev $3.6-3.7M (+71-77% YoY); FY2021 rev $13.0-13.1M (+113-116% YoY); FY2022 guidance $20-23M","bullets":["Preliminary Q4 2021 revenue $3.6-$3.7M, up 71-77% YoY vs $2.1M.","Full year 2021 revenue $13.0-$13.1M, up 113-116% from $6.1M in 2020.","U.S. heart failure revenue $8.4M, Europe $3.9M, U.S. legacy $0.7M for 2021.","Active implanting centers grew to 46 as of Dec 31, 2021 from 38 as of Sep 30, 2021.","FY2022 revenue guidance $20-$23M; Q1 2022 expected $3.6-$4.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-002514","json":"https://secwatch.observer/filing/0001104659-22-002514.json","markdown":"https://secwatch.observer/filing/0001104659-22-002514.md","text":"https://secwatch.observer/filing/0001104659-22-002514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465922002514/0001104659-22-002514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465922002514/tm222384d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:13:48.685649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}